You’ve spent months working on the asset. The clinical strategy has been debated. The data...
Every Project Plan Assumes People Don’t Leave. Reality Check: They Do. A few years...
This past month, I have been immersed in obesity science, and one thing’s clear: not every...
Intro Teams often fail not because of a lack of data, but because of research that...
It has been a quiet summer on the post front with holidays and then a few active projects...
Intro At the end of May, Eli Lilly announced a $1 billion deal with Site One Therapeutics...
You’ve spent months working on the asset. The clinical strategy has been debated. The data have been reviewed from every angle. The...
Every Project Plan Assumes People Don’t Leave. Reality Check: They Do. A few years ago, I took over a project that was...
This past month, I have been immersed in obesity science, and one thing’s clear: not every pathway moves the scales. After dissecting...
Intro Teams often fail not because of a lack of data, but because of research that confirms what they already believe. The...
You’ve spent months working on the asset. The clinical strategy has been debated. The data have been...
Every Project Plan Assumes People Don’t Leave. Reality Check: They Do. A few years ago, I took...
This past month, I have been immersed in obesity science, and one thing’s clear: not every pathway...
Intro Teams often fail not because of a lack of data, but because of research that confirms what...
It has been a quiet summer on the post front with holidays and then a few active projects keeping us...
Intro At the end of May, Eli Lilly announced a $1 billion deal with Site One Therapeutics, a company...
When you read the Pharma news sites and analysis on LinkedIn about drug patent cliffs, you might...
With the sun out and a few projects wrapping up, I have enjoyed longer dog walks and catching up on...
Introduction: Spotting the Threat You Didn’t Expect This week’s article is based on a project...